Broadly Protective Adenovirus-based Multivalent Vaccines Against Highly Pathogenic Avian Influenza Viruses for Pandemic Preparedness

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 May 3

PMID 23638099

Citations 32

Authors

Sai V Vemula

Yadvinder S Ahi

Anne-Marie Swaim

Jacqueline M Katz

Ruben Donis

Suryaprakash Sambhara

Suresh K Mittal

Affiliations

Soon will be listed here.

Abstract

Recurrent outbreaks of H5, H7 and H9 avian influenza viruses in domestic poultry accompanied by their occasional transmission to humans have highlighted the public health threat posed by these viruses. Newer vaccine approaches for pandemic preparedness against these viruses are needed, given the limitations of vaccines currently approved for H5N1 viruses in terms of their production timelines and the ability to induce protective immune responses in the absence of adjuvants. In this study, we evaluated the feasibility of an adenovirus (AdV)-based multivalent vaccine approach for pandemic preparedness against H5, H7 and H9 avian influenza viruses in a mouse model. Replication-defective AdV vectors expressing hemagglutinin (HA) from different subtypes and nucleoprotein (NP) from one subtype induced high levels of humoral and cellular immune responses and conferred protection against virus replication following challenge with H5, H7 and H9 avian influenza virus subtypes. Inclusion of HA from the 2009 H1N1 pandemic virus in the vaccine formulation further broadened the vaccine coverage. Significantly high levels of HA stalk-specific antibodies were observed following immunization with the multivalent vaccine. Inclusion of NP into the multivalent HA vaccine formulation resulted in the induction of CD8 T cell responses. These results suggest that a multivalent vaccine strategy may provide reasonable protection in the event of a pandemic caused by H5, H7, or H9 avian influenza virus before a strain-matched vaccine can be produced.

Citing Articles

Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine.

Cowling B, Okoli G Drugs. 2024; 84(9):1013-1023.

PMID: 39167316 PMC: 11438668. DOI: 10.1007/s40265-024-02083-8.

Development of NP-Based Universal Vaccine for Influenza A Viruses.

Sayedahmed E, Elshafie N, Dos Santos A, Jagannath C, Sambhara S, Mittal S Vaccines (Basel). 2024; 12(2).

PMID: 38400140 PMC: 10892571. DOI: 10.3390/vaccines12020157.

Enhancement of mucosal innate and adaptive immunity following intranasal immunization of mice with a bovine adenoviral vector.

Sayedahmed E, Elshafie N, Zhang G, Mohammed S, Sambhara S, Mittal S Front Immunol. 2023; 14:1305937.

PMID: 38077380 PMC: 10702558. DOI: 10.3389/fimmu.2023.1305937.

Impact of an autophagy-inducing peptide on immunogenicity and protection efficacy of an adenovirus-vectored SARS-CoV-2 vaccine.

Sayedahmed E, Araujo M, Silva-Pereira T, Chothe S, Elkashif A, Alhashimi M Mol Ther Methods Clin Dev. 2023; 30:194-207.

PMID: 37502665 PMC: 10299838. DOI: 10.1016/j.omtm.2023.06.009.

Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections.

Elkashif A, Alhashimi M, Sayedahmed E, Sambhara S, Mittal S Clin Transl Immunology. 2021; 10(10):e1345.

PMID: 34667600 PMC: 8510854. DOI: 10.1002/cti2.1345.

References

Smith G, Vijaykrishna D, Bahl J, Lycett S, Worobey M, Pybus O . Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature. 2009; 459(7250):1122-5. DOI: 10.1038/nature08182. View

McElrath M, De Rosa S, Moodie Z, Dubey S, Kierstead L, Janes H . HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet. 2008; 372(9653):1894-1905. PMC: 2774110. DOI: 10.1016/S0140-6736(08)61592-5. View

Ekiert D, Friesen R, Bhabha G, Kwaks T, Jongeneelen M, Yu W . A highly conserved neutralizing epitope on group 2 influenza A viruses. Science. 2011; 333(6044):843-50. PMC: 3210727. DOI: 10.1126/science.1204839. View

Goji N, Nolan C, Hill H, Wolff M, Noah D, Williams T . Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. J Infect Dis. 2008; 198(5):635-41. DOI: 10.1086/590916. View

Parrish C, Kawaoka Y . The origins of new pandemic viruses: the acquisition of new host ranges by canine parvovirus and influenza A viruses. Annu Rev Microbiol. 2005; 59:553-86. DOI: 10.1146/annurev.micro.59.030804.121059. View

Singh N, Pandey A, Mittal S . Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target. Expert Rev Mol Med. 2010; 12:e14. PMC: 2904949. DOI: 10.1017/S1462399410001432. View

Ng P, Parks R, Cummings D, Evelegh C, Sankar U, Graham F . A high-efficiency Cre/loxP-based system for construction of adenoviral vectors. Hum Gene Ther. 1999; 10(16):2667-72. DOI: 10.1089/10430349950016708. View

Cox R, Madhun A, Hauge S, Sjursen H, Major D, Kuhne M . A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine. 2009; 27(13):1889-97. DOI: 10.1016/j.vaccine.2009.01.116. View

Roy S, Kobinger G, Lin J, Figueredo J, Calcedo R, Kobasa D . Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein. Vaccine. 2007; 25(39-40):6845-51. PMC: 2748222. DOI: 10.1016/j.vaccine.2007.07.035. View

10.

Van Kampen K, Shi Z, Gao P, Zhang J, Foster K, Chen D . Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine. 2004; 23(8):1029-36. DOI: 10.1016/j.vaccine.2004.07.043. View

11.

Tan G, Krammer F, Eggink D, Kongchanagul A, Moran T, Palese P . A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo. J Virol. 2012; 86(11):6179-88. PMC: 3372189. DOI: 10.1128/JVI.00469-12. View

12.

Thomas P, Keating R, Hulse-Post D, Doherty P . Cell-mediated protection in influenza infection. Emerg Infect Dis. 2006; 12(1):48-54. PMC: 3291410. DOI: 10.3201/eid1201.051237. View

13.

Stephenson K, Hural J, Buchbinder S, Sinangil F, Barouch D . Preexisting adenovirus seropositivity is not associated with increased HIV-1 acquisition in three HIV-1 vaccine efficacy trials. J Infect Dis. 2012; 205(12):1806-10. PMC: 3415893. DOI: 10.1093/infdis/jis285. View

14.

Subbarao K, Joseph T . Scientific barriers to developing vaccines against avian influenza viruses. Nat Rev Immunol. 2007; 7(4):267-78. PMC: 7097526. DOI: 10.1038/nri2054. View

15.

Stephenson I, Nicholson K, Hoschler K, Zambon M, Hancock K, DeVos J . Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N Engl J Med. 2008; 359(15):1631-3. DOI: 10.1056/NEJMc0805274. View

16.

Ahi Y, Bangari D, Mittal S . Adenoviral vector immunity: its implications and circumvention strategies. Curr Gene Ther. 2011; 11(4):307-20. PMC: 4009923. DOI: 10.2174/156652311796150372. View

17.

Ekiert D, Bhabha G, Elsliger M, Friesen R, Jongeneelen M, Throsby M . Antibody recognition of a highly conserved influenza virus epitope. Science. 2009; 324(5924):246-51. PMC: 2758658. DOI: 10.1126/science.1171491. View

18.

Ikonen N, Strengell M, Kinnunen L, Osterlund P, Pirhonen J, Broman M . High frequency of cross-reacting antibodies against 2009 pandemic influenza A(H1N1) virus among the elderly in Finland. Euro Surveill. 2010; 15(5). View

19.

Saito T, Lim W, Suzuki T, Suzuki Y, Kida H, Nishimura S . Characterization of a human H9N2 influenza virus isolated in Hong Kong. Vaccine. 2001; 20(1-2):125-33. DOI: 10.1016/s0264-410x(01)00279-1. View

20.

LaMere M, Lam H, Moquin A, Haynes L, Lund F, Randall T . Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. J Immunol. 2011; 186(7):4331-9. PMC: 3159153. DOI: 10.4049/jimmunol.1003057. View